Wolfe Research analyst Andy Chen initiated coverage of Kymera Therapeutics with a Peer Perform rating. The company’s KT-474 accounts for most of the enterprise value, whereas investors will continue to ascribe little value to the STAT6 and TYK2 pipeline as well as Kymera’s immuno-oncology products, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KYMR:
- Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
- Kymera Therapeutics provides 2024 corporate goals
- Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
- Kymera Therapeutics sees cash runway into 1H27
